Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanabenz. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanabenz SCHEMBL15390 | 1.00 | TAAR1 (1.00) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| Guanabenz SCHEMBL3054917 | 0.90 | NPSR1 (1.00) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL17704923 | 0.85 | SLC22A1 (0.73) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| Guanoxabenz SCHEMBL122727 | 0.82 | SLC22A1 (0.69) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| Guanoxabenz SCHEMBL19715284 | 0.82 | SLC22A1 (0.69) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| Guanoxabenz SCHEMBL17802522 | 0.82 | SLC22A1 (0.69) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL8925014 | 0.80 | SLC22A1 (0.67) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL22761365 | 0.80 | SLC22A1 (0.67) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL8925019 | 0.80 | SLC22A1 (0.67) | TAAR1SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL30872248 | 0.79 | NPSR1 (1.00) | TAAR1SLC22A1HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4027039-A | ADMINISTERING AMINOGUANIDINE, GUANIDINE, OR 1-(SEC-BUTYLIDENEAMINO)GUANIDINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-31 | — | — | US | claimed |
| US-20210353749-A1 | GUANABENZ AS AN ADJUVANT FOR IMMUNOTHERAPY | Université Catholique de Louvain (BE) | 2021-11-18 | — | — | US | disclosed |
| US-20210330616-A1 | AMELIORATING AGENT FOR OBESITY-RELATED METABOLIC DISEASE | METABOLIC AND OBESE RESEARCH SCIENCE CORPORATION (JP) | 2021-10-28 | — | — | US | disclosed |
| CN-113316449-A | Guanabenz as an adjuvant for immunotherapy | 鲁汶大学 | 2021-08-27 | — | — | CN | disclosed |
| EP-3848023-A1 | AMELIORATING AGENT FOR OBESITY-RELATED METABOLIC DISEASE | Metabolic and Obese Research Science Corporation (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-2508182-B1 | Hydralazine for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2508183-B1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014081856-A2 | LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | AZZAZY HASSAN (EG) | 2014-05-30 | — | — | WO | disclosed |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-07 | — | — | US | disclosed |
| US-8318741-B2 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-11-27 | — | — | US | disclosed |
| US-8088773-B2 | Therapeutic compositions and methods | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080275129-A1 | Methods and Pharmaceutical Compositions for the Treatment of Neurological Damage | ACURE PHARMA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1885371-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | The Texas A & M University System (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060276458-A1 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM | 2006-12-07 | — | — | US | disclosed |
| WO-2006124324-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1288238-A1 | Compositions of matter having bioactive properties | Schmitz, Robert A. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6299892-B1 | INCORPORATING INTO DELIVERY VEHICLES SUITABLE FOR EFFECTING DESIRED ANTIMICROBIAL USE, SOAPS AND DETERGENTS | SCHMITZ ROBERT A (US) | 2001-10-09 | — | — | US | disclosed |
| EP-0156592-A2 | Substained release pharmaceutical capsules | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
| US-4312886-A | (286-DICHLOROBENZYLIDENE)AMINO-GUANIDINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
| US-4006249-A | Systemic treatment of psoriasis | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276458-A1 | Therapeutic compositions and methods | PDE6H, PDE6C, PDE6D | ADRA2A 3354/4885ADRA2B 3926/4885ADRA2C 2926/4885 |
| US-20210330616-A1 | AMELIORATING AGENT FOR OBESITY-RELATED METABOLIC DISEASE | GPR119, GID4, GCKR | ADRA2A 1880/4885ADRA2B 1497/4885ADRA2C 1501/4885 |
| US-20210353749-A1 | GUANABENZ AS AN ADJUVANT FOR IMMUNOTHERAPY | ICOS, CD274, IL15 | ADRA2A 414/4885ADRA2B 267/4885ADRA2C 533/4885 |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | ADRA2A 3354/4885ADRA2B 3926/4885ADRA2C 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.